Claim your 30% discount on Global Market Reports with code ONLINE30. Limited time only.

Claim your 30% discount on Global Market Reports with code ONLINE30. Limited time only.

What Are the Forecasted Growth Rate and Market Size of the Non Hodgkin Lymphoma (NHL) Market?

The market size of non-hodgkin lymphoma (NHL) has seen significant growth in the recent past. It is projected to increase from $10.11 billion in 2024 to $10.86 billion in 2025, reflecting a compound annual growth rate (CAGR) of 7.5%. This growth during the historic period is due to factors such as a higher frequency of NHL cases, advancements in detection methods including chemotherapy and immunotherapy, clinical research, drug development, and enhanced survival rates.

Anticipated to experience robust expansion in the coming years, the market for non hodgkin lymphoma (NHL) is predicted to extend to “$15 billion by 2029, achieving a compound annual growth rate (CAGR) of 8.4%. Factors contributing to the growth within the forecasted period encompass escalating elderly population, advancements in targeted treatments, breakthroughs in immunotherapy, strategies in precision medicine, enhanced awareness, and early detection. Upcoming trends within the forecast timeline involve the emergence of biosimilars, the incorporation of next-generation sequencing, the utilization of car-t cell therapies, new chemotherapy agents, as well as real-world evidence and progress in outcomes research.

Download The Free Sample Report Here:

https://www.thebusinessresearchcompany.com/sample.aspx?id=10676&type=smp

Which Factor Is Shaping The Future Of The Non Hodgkin Lymphoma (NHL) Market?

The growth of the non-Hodgkin lymphoma market is anticipated to be driven by the high prevalence of the disease. Non-Hodgkin lymphoma is a cancer that originates within the lymphatic system, an integral part of the body’s immune response. When we discuss the prevalence of non-Hodgkin lymphoma, we refer to the count of individuals in a population who are either recently diagnosed or are currently living with the disease. The treatment available for non-Hodgkin lymphoma plays a crucial role in enhancing life outcomes for those diagnosed by promoting the management and containment of cancer cells. For example, the American Cancer Society, a leading cancer health organization based in the US, stated in January 2023 that non-Hodgkin lymphoma constitutes 4% of all cancer cases. In 2023, around 80,550 Americans, including 44,880 men and 35,670 women, are projected to be impacted by it. The organization also predicts that 20,180 individuals will succumb to the disease in 2023. In May 2022, the Canadian Cancer Society, a prominent national cancer charity in Canada, forecasted that 11,400 Canadians would be diagnosed with non-Hodgkin lymphoma in the year 2022 and that it would lead to the deaths of 3,000 Canadians. Hence, it is the high prevalence of non-Hodgkin lymphoma that is fuelling the growth of the non-Hodgkin lymphoma market.

The non hodgkin lymphoma (nhl) market covered in this report is segmented –

1) By Type: B-Cell Lymphoma, T-Cell Lymphoma

2) By Treatment: Surgery, Stem Cell Transplant, Chemotherapy, Immunotherapy, Targeted Therapy, Radiation Therapy

3) By Route of Administration: Oral, Parenteral, Other Routes of Administration

4) By Distribution Channel: Hospital Pharmacy, Retail Pharmacy, Online Pharmacy, Other Distribution Channels

5) By End-Users: Hospitals, Homecare, Specialty Centers, Other End Users

Subsegments:

1) By B-Cell Lymphoma: Diffuse Large B-Cell Lymphoma (DLBCL), Follicular Lymphoma, Chronic Lymphocytic Leukemia (CLL), Mantle Cell Lymphoma, Burkitt Lymphoma, Marginal Zone Lymphoma, Primary Mediastinal B-Cell Lymphoma

2) By T-Cell Lymphoma: Peripheral T-Cell Lymphoma (PTCL), Anaplastic Large Cell Lymphoma (ALCL), Cutaneous T-Cell Lymphoma (CTCL), T-Cell Lymphoblastic Lymphoma, Adult T-Cell Leukemia/Lymphoma (ATLL)

What Future Market Trends Are Projected For The Non Hodgkin Lymphoma (NHL) Industry?

The rise of advancements in drug innovations is a significant trend that is becoming increasingly prevalent in the non-Hodgkin lymphoma market. Companies active in the non-Hodgkin market are putting a strong emphasis on the creation of new products to maintain their market standing. In December 2022, for example, Genentech Inc., a biotechnology firm from the United States, gained FDA approval for Lunsumio, a groundbreaking bispecific antibody used for the treatment of relapsed or refractory follicular lymphoma. This antibody, a novel class of immunotherapy providing fixed-duration cancer treatment, is readily accessible and does not require waiting to receive the treatment. The FDA’s endorsement of Lunsumio is based on the successful results from Phase II GO29781 research involving patients with extensively pretreated FL who are at a high risk of disease progression or unresponsive to previous treatments.

Which Companies Hold The Largest Market Share In The Non Hodgkin Lymphoma (NHL) Sector?

Major companies operating in the non hodgkin lymphoma (NHL) market include Bayer AG, Teva Pharmaceutical Industries Ltd., F. Hoffmann La Roche Ltd., Merck & Co. Inc., Eli Lilly and Co., Novartis AG, GlaxoSmithKline plc, AbbVie Inc., AstraZeneca plc, Takeda Pharmaceutical Company Limited, Bristol Myers Squibb Co., Pfizer Inc., Celgene Corporation, Sanofi S.A., Janssen Pharmaceuticals Inc., Johnson & Johnson, Biogen Idec, Boehringer Ingelheim GmbH, Eisai Co. Ltd., Gilead Sciences, Incyte Corporation, Karyopharm Therapeutics, Kite Pharma Inc., Kyowa Hakko Kirin Co. Ltd., MorphoSys AG, Nordic Nanovector ASA, Ono Pharmaceutical Co. Ltd., Seattle Genetics Inc., Spectrum Pharmaceuticals Inc.

https://www.thebusinessresearchcompany.com/report/non-hodgkin-lymphoma-nhl-global-market-report

How Does Regional Performance Compare Across The Non Hodgkin Lymphoma (NHL) Industry?

North America was the largest region in the non-Hodgkin lymphoma (NHL) market in 2024.Asia-Pacific is expected to be the fastest-growing region in the global non-Hodgkin lymphoma (NHL) market report during the forecast period. The regions covered in the non-Hodgkin lymphoma (NHL) market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa

Request For A Customized Report:

https://www.thebusinessresearchcompany.com/customise?id=10676&type=smp

About The Business Research Company:

With over 15000+ reports from 27 industries covering 60+ geographies, The Business Research Company has built a reputation for offering comprehensive, data-rich research and insights. Armed with 1,500,000 datasets, the optimistic contribution of in-depth secondary research, and unique insights from industry leaders, you can get the information you need to stay ahead in the game.

Get in touch with us:

The Business Research Company: https://www.thebusinessresearchcompany.com/

Americas +1 310-496-7795

Asia +44 7882 955267 & +91 8897263534

Europe +44 7882 955267

Email us at info@tbrc.info

Follow us on:

LinkedIn: https://in.linkedin.com/company/the-business-research-company

YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ

Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model